Rifampin and Rifabutin Resistance Mechanism in Helicobacter pylori

Helicobacter pylori resistance to rifabutin in the last 7 years.

A low rate of resistance (0.24%) to rifabutin was noted in Helicobacter pylori strains isolated from 414 Japanese patients. The only rifabutin-resistant strain detected showed a point mutation in the rpoB gene and was isolated from a patient with a history of rifampin treatment for pulmonary tuberculosis.

Update on rifampin and rifabutin drug interactions.

Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum c...

Drug Resistance in Helicobacter Pylori.

Background Helicobacter pylori has a worldwide distribution and is associated with the pathogenesis of various diseases of the digestive system. Treatment to eradicate this microorganism involves the use of a combination of antimicrobials, such as amoxicillin, metronidazole, clarithromycin, and levofloxacin, combined with proton pump inhibitors. Although the current therapy is effective, a high...

Drug Resistance in Helicobacter Pylori.

H. pylori infection determines an important acute and chronic gastric mucosa inflammation. If untreated, the inflammation may remain forever, being infrequently spontaneously eliminated. It is known that chronic gastritis caused by this infection may lead to atrophic gastritis, intestinal metaplasia and dysplasia, thus setting the role of H. pylori in gastric carcinogenesis cascade(4,7). Theref...

Drug resistance in Helicobacter pylori.